May 16, 2024
Headlines

Cancer

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab’s Promising Data (NASDAQ:ZYME)

admin018 mins

Caiaimage/Martin Barraud/iStock via Getty Images Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biotechnology company focused on developing innovative therapies for challenging to treat cancers and other serious conditions. ZYME leverages proprietary platforms concentrated on Multispecific Antibody Therapeutics and Antibody-Drug Conjugate Technologies. These platforms drive the creation of treatments to support a dynamic pipeline of drug candidates,…

Read More

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering (NASDAQ:GRTS)

admin017 mins

red_moon_rise In my previous Gritstone bio (NASDAQ:GRTS) article, I discussed how the company’s technology could make it a cutting-edge infectious disease firm with a strong list of collaborations that could rival Moderna (MRNA) and BioNTech (BNTX). However, I also noted that the company’s biggest upside potential was its oncology programs, notably GRANITE, which could transform…

Read More

MacroGenics: Evaluating Buy Status After A 200% Surge On Prostate Cancer Prospects (MGNX)

admin09 mins

Klaus Vedfelt/DigitalVision via Getty Images Introduction MacroGenics‘ (NASDAQ:MGNX) stock is up 230% since my “Buy” recommendation in September. Seeking Alpha Two major variables have contributed to the run. One, the macroeconomics (prospects of rate cuts later this year by the Federal Reserve) have been favorable to the biotech sector. Many stocks are up significantly without…

Read More

Moderna: MRNA-4157 Cancer Vaccine Data Points To A Future Beyond Spikevax (NASDAQ:MRNA)

admin020 mins

hapabapa Moderna (NASDAQ:MRNA) and Merck (MRK) reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former’s cancer vaccine, MRNA-4157. The companies recently reported promising results from a Phase II trial, demonstrating the vaccine’s efficacy in treating melanoma. The data revealed a noteworthy 49% reduction in the possibility of cancer recurrence or death…

Read More

Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data (NASDAQ:AMAM)

admin013 mins

Kitsawet Saethao/iStock via Getty Images Ambrx Biopharma Inc. (NASDAQ:AMAM) has made great progress in advancing its pipeline towards several types of cancer therapeutics. One such drug would be the use of ARX517, which is an anti-PSMA antibody drug conjugate [ADC], which is being developed for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]….

Read More

Nurix Therapeutics: The Prospects Of A ‘New Class’ Of Cancer Drug (NASDAQ:NRIX)

admin010 mins

marchmeena29/iStock via Getty Images Topline Summary Nurix Therapeutics (NASDAQ:NRIX) is a biotech company specializing in the development of protein degraders, which are intended as a new class of cancer therapeutic exploiting known targets, some of which have currently approved targeted agents already approved. While their approach is novel and interesting, with very early signs of…

Read More

AI Might Help Cure Cancer and Reduce Working Week to 3.5 Days

admin06 mins

As JPMorgan’s CEO has stated, the company has already found more than 300 use cases for AI. The applied AI initiatives include virtual assistants, anomaly detection, news analytics, quantitative client intelligence, smart documents, intelligent pricing, and more. On Monday, JPMorgan Chase & Co (NYSE: JPM) CEO Jamie Dimon had an interview with Bloomberg TV where he…

Read More

Navigating ORIC’s Robust Strategy Against Cancer Drug Resistance (NASDAQ:ORIC)

admin010 mins

kyonntra/E+ via Getty Images Introduction ORIC Pharmaceuticals (NASDAQ:ORIC), a clinical-stage biopharmaceutical company, is dedicated to addressing drug resistance in cancer. Their clinical portfolio includes ORIC-114 for EGFR and HER2 mutations, ORIC-533 targeting CD73 to enhance chemotherapy and immunotherapy, and ORIC-944 for advanced prostate cancer. They are also engaged in early-stage projects to combat various other…

Read More

Autolus Therapeutics: Innovating T Cell Cancer Treatments (NASDAQ:AUTL)

admin012 mins

CIPhotos Introduction Autolus Therapeutics (NASDAQ:AUTL) is a leading biopharmaceutical firm innovating T cell therapies for cancer treatment. They’ve developed unique T cell programming technologies, with “obe-cel” showing promise in trials and anticipated FDA submission by 2023’s end. Partnering with University College London, they’re involved in the CARPALL and ALLCAR19 studies. In 2023, their Stevenage-based facility,…

Read More

Arvinas’ Potential In Treating ER+, HER2- Breast Cancer (NASDAQ:ARVN)

admin012 mins

Anchiy Introduction Arvinas (NASDAQ:ARVN) is a clinical-stage biotech firm pioneering therapies to treat severe diseases by degrading disease-causing proteins. Using their unique PROTAC Discovery Engine, they design PROTAC targeted protein degraders to utilize the body’s natural disposal system, aiming for advantages over traditional therapies and gene medicines. They specifically target proteins previously deemed ‘undruggable,’ with…

Read More